Mammalian phosphodiesterases (PDEs) hydrolyze cyclic nucleotides and are essential in the regulation of cAMP-mediated signal transduction. They constitute a large group of isozymes that can be categorized into families or types. Different PDE types display characteristic tissue distributions, distinctive biochemical properties and unique inhibitor profiles. These features account for the physiological properties of these enzymes and are directly relevant to the efficacy of PDE inhibitors as therapeutic agents. Sequence alignment of different PDE types shows some conservation that is likely to reflect requirements for catalytic activity. The specific regions, and the particular residues, responsible for the distinctive properties of each PDE type are not yet known, however. We previously devised a yeast expression system for analysis of mammalian PDEs and for genetic selection of drug resistant mutants of these enzymes. Deletions and point mutations were used to identify regions and residues necessary for activity and for drug binding. We now propose to examine isozyme specificity in several PDE types, making use of a modified approach that builds on the strengths of our reconstituted yeast system. We will utilize chimeric PDE enzymes to determine which residues are sufficient, within the context of a PDE, to confer the unique biochemical properties and inhibitor susceptibility of each PDE type. These data will be used to optimize the selection of drug-resistant mutants leading to the identification of specific residues that account for these properties. Experiments to examine substrate specificity are also proposed. The results will address whether isozyme specificity determinants are localized in a pattern that is conserved across divergent forms of PDEs. In addition, the information derived from these studies should be useful for PDE-centered therapeutics where distinction among isozymes is crucial. It may also serve as a model for the analysis of other complex isozyme families.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS031911-06
Application #
2891880
Study Section
Physical Biochemistry Study Section (PB)
Program Officer
Jacobs, Margaret
Project Start
1993-08-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2001-05-31
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Pharmacology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Huai, Qing; Colicelli, John; Ke, Hengming (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42:13220-6
Dym, Orly; Xenarios, Ioannis; Ke, Hengming et al. (2002) Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol 61:20-5
Atienza, J M; Suh, M; Xenarios, I et al. (2000) Human ERK1 induces filamentous growth and cell wall remodeling pathways in Saccharomyces cerevisiae. J Biol Chem 275:20638-46
Atienza, J M; Susanto, D; Huang, C et al. (1999) Identification of inhibitor specificity determinants in a mammalian phosphodiesterase. J Biol Chem 274:4839-47
Pillai, R; Staub, S F; Colicelli, J (1994) Mutational mapping of kinetic and pharmacological properties of a human cardiac cAMP phosphodiesterase. J Biol Chem 269:30676-81
Pillai, R; Kytle, K; Reyes, A et al. (1993) Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase. Proc Natl Acad Sci U S A 90:11970-4